Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Executive Officer
August 08, 2022 18:36 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases,...
Agios Reports Business Highlights and Second Quarter 2022 Financial Results
August 04, 2022 07:00 ET
|
Agios Pharmaceuticals, Inc.
– Generated $3.1 Million in Net U.S. Revenue for First Full Quarter of PYRUKYND® (mitapivat) Sales – – Brian Goff to Become Chief Executive Officer at Agios on August 8, 2022, Leveraging 30+ Years of...
Agios to Webcast Conference Call of Second Quarter 2022 Financial Results on August 4, 2022
July 14, 2022 07:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases,...
Agios Appoints Brian Goff as Chief Executive Officer
July 12, 2022 16:01 ET
|
Agios Pharmaceuticals, Inc.
– Current CEO, Jackie Fouse, Ph.D., to Transition to Chair of Board of Directors Effective August 8, 2022 – – Agios to Host Investor Webcast Today at 4:30pm ET – CAMBRIDGE, Mass., July 12, 2022 ...
Agios Presents New Clinical Data Supporting the Benefits of PYRUKYND® (mitapivat) Treatment in Adults with PK Deficiency at European Hematology Association Annual Congress
June 10, 2022 10:30 ET
|
Agios Pharmaceuticals, Inc.
– Treatment with PYRUKYND® Associated with Early and Robust Hemoglobin Responses in Phase 3 ACTIVATE and Extension Studies; Approximately One-Third of Patients Achieved Normal Hemoglobin Levels at...
Agios Announces Evolution of Research Organization
May 16, 2022 16:15 ET
|
Agios Pharmaceuticals, Inc.
– Sarah Gheuens, M.D., Ph.D., to be Named Head of R&D, Chief Medical Officer; Chief Scientific Officer Bruce Car to Step Down at the End of July – – Company to Focus Internal Research Efforts on...
Agios to Present Clinical and Translational Data at the European Hematology Association Annual Congress
May 12, 2022 10:00 ET
|
Agios Pharmaceuticals, Inc.
– Agios to Present New Patient-Reported Outcomes (PRO) Data from ACTIVATE Phase 3 Study of PYRUKYND® (mitapivat) in Adults with PK Deficiency Who Do Not Receive Regular Transfusions – – Agios to...
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 17, 2022
May 10, 2022 07:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases,...
Agios Reports Business Highlights and First Quarter 2022 Financial Results
May 05, 2022 07:00 ET
|
Agios Pharmaceuticals, Inc.
– Received U.S. FDA Approval for PYRUKYND®, the First Therapy for the Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase (PK) deficiency and Agios’ First Genetically Defined Disease...
Agios to Webcast Conference Call of First Quarter 2022 Financial Results on May 5, 2022
April 21, 2022 07:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases,...